Oncolytic Virus Growth Method with Anticancer Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antitumor therapies for malignant tumors have high mortality rates and adverse effects, necessitating a new therapeutic method with improved safety and efficacy.
Innovation Solution
Combining oncolytic viruses, such as coxsackievirus A11 or adenovirus, with anticancer agents like oxaliplatin, SN-38, or 5-FU to enhance antitumor effects while minimizing adverse effects by promoting virus proliferation and receptor expression on cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antitumor therapies (surgery, radiation, chemotherapy) are used, then tumor treatment is achieved, but mortality rate remains high and adverse effects are significant
Solution Approach 1:
The patent combines oncolytic viruses with anticancer agents (oxaliplatin, plant alkaloids, antimetabolites) to create a synergistic therapy. The virus-infected cancer cells are merged with chemically treated cells, where the virus provides direct cytocidal effect and the chemotherapy agents enhance virus proliferation and receptor expression, achieving superior antitumor effect with reduced adverse effects compared to conventional single-mode therapies
Solution Approach 2:
The oncolytic virus acts as an intermediary between the anticancer agent and the cancer cell. The virus enters the cell, utilizes the anticancer agent to enhance its proliferation and receptor expression, and then mediates the cytocidal effect. This intermediary mechanism allows the therapy to target cancer cells specifically while reducing off-target adverse effects
2Productivity
If oncolytic virus therapy alone is used, then direct cytocidal effect is achieved, but antitumor effect may be limited without combination therapy
Solution Approach 1:
The anticancer agent is administered before or concurrently with the oncolytic virus to perform preliminary actions: enhancing virus receptor expression on cancer cells and promoting virus proliferation. This preliminary action ensures that when the virus enters the cell, it can rapidly replicate and exert its cytocidal effect, thereby enhancing overall antitumor productivity and reliability
3Productivity
If enteroviruses are used, then high proliferation rate and rapid antitumor effect are achieved, but safety concerns may arise
Solution Approach 1:
The patent applies local quality by selecting specific enterovirus strains (CVA11, EV4) that have been characterized to have high proliferation rates in cancer cells but low pathogenicity in humans. The therapy is localized to cancer tissue through virus-specific receptor binding, ensuring that the high proliferation rate benefits cancer cells while the low pathogenicity protects human tissues, thus resolving the contradiction between productivity and safety
Data Source
AI summary
Provided is antitumor therapy using oncolytic viruses which exhibits an excellent antitumor effect and has reduced adverse effects.An antitumor agent, comprising a combination of an oncolytic virus and an anticancer agent selected from the group consisting of oxaliplatin, an anticancer plant alkaloid, and an antimetabolite.